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Failure of atrial natriuretic peptide to induce natriuresis in aortocaval
listula dogs. Creation of an aortocaval fistula (ACF) in dogs induces salt
and water retention, activation of the renin-angiotensin and adrenergic
nervous systems and renal papillary ischemia associated with high
levels of circulating atrial natriuretic peptide (ANP). The effects of
intrarenal ANP (1.2 g/min) infusion on systemic and renal hemody-
namics, renal excretory function, renal output of renin and norepineph-
rifle (NE) and papillary plasma flow (PPF) were studied in both normal
and ACF dogs. ANP did not alter systemic hemodynamics in either
group, but led to a significant increase in renal blood flow (RBF),
glomerular filtration rate (GFR), urine flow rate (V), sodium excretion
(UNaV) and fractional excretion of sodium (FENa), and a significant
decrease in renal vascular resistance (RYR) and urine osmolality
(Uom) in normal dogs. GFR, RBF, RVR, V, UNaV, FENa and Uosm
remained unchanged, however, in ACF dogs. In ACF dogs, both renal
renin and NE output were significantly greater during baseline and
remained significantly greater following ANP infusion, associated with
a significantly lower PPF compared with normal dogs. These data
suggest that ACF dogs are resistant to the renal effects of ANP, which
can neither mitigate the hormonal mediators of sodium retention nor
reverse the papillary ischemia observed in this model.
Atrial natriuretic peptide (ANP) is a biologically active pep-
tide which has been sequenced, synthesized and shown to
possess potent effects on systemic and renal hemodynamics and
renal excretory function [1]. Previous studies have suggested
that ANP may increase GFR [2, 3] and inner medullary blood
flow [1, 4-6] in addition to inhibiting sodium reabsorption in the
medullary collecting duct [7, 81. Although controversy exists as
to its role as a regulator of sodium balance, ANP has been
shown to be released into the circulation with either acute [9] or
chronic [10] volume expansion associated with both a natriure-
sis and diuresis.
Creation of an aortocaval fistula (ACF) decreases peripheral
vascular resistance, which raises cardiac output and activates
the renin-angiotensin and adrenergic systems, leading to a
decrease in papillary plasma flow (PPF) and sodium retention
[11]. The state of avid sodium retention in the ACF dogs may
later convert into a neutral sodium balance stage which may be
related to the increase in endogenous ANP and suppression of
the renin-angiotensin-aldosterone system [12]. Studies per-
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formed in ACF rats, however, have demonstrated a blunted
natriuretic and diuretic response following the intravenous
administration of ANP [13]. In this latter study a decrease in
arterial pressure induced by ANP may have attenuated its
natriuretic effects.
Although several studies have examined the effects of ANP
on plasma levels of renin and norepinephrine (NE) [14—27] the
effect of ANP on these mediators of sodium retention in the
kidney has not been studied. The present study was thus
performed to evaluate the effects of intrarenally administered
ANP on renal excretory function, the renal renin and adrenergic
systems, and inner medullary hemodynamics in normal and
ACF dogs, while systemic circulatory function remained unal-
tered from the baseline state.
Methods
Experiments were performed on female mongrel dogs weigh-
ing 19.2 to 24.0 kg. All dogs received a diet containing 60 mEq
sodium and 40 mEq potassium per day. In nine of the dogs,
weighing 21.3 0.6 kg (SE), an ACF was constructed midway
between the renal arteries and aortic bifurcation under aseptic
technique. After isolation of the aorta and inferior vena cava,
both were partially clamped and a 0.8 mm/kg body wt contigu-
ous longitudinal slit was made in the vessels and the edges sewn
with one continuous 5-0 non-absorbable cardiovascular suture.
During the creation of the ACF the circulation to the hindquar-
ters was never compromised. All animals survived surgery and
were studied 8 1 days later at a time when they exhibited avid
sodium retention as manifested by ascites and edema. Addition-
ally, eight normal dogs, weighing 20,3 0.6 kg were also
studied after metabolic studies proved them to be in sodium
balance.
On the morning of the acute experiment, venous blood was
drawn from conscious animals for determination of plasma
renin activity (PRA), NE and ANP levels. The dogs were then
anesthetized with sodium pentobarbital (30 mg/kg body wt)
intravenously. Light anesthesia was maintained throughout the
experiment by the administration of additional anesthetic, as
necessary. An endotracheal tube was inserted and ventilation
was regulated via a respirator. The urinary bladder was cathe-
terized with a Foley catheter for urine collection. A catheter
was placed in the thoracic aorta via a femoral artery to allow
blood sampling, as well as determination of mean arterial blood
pressure (MAP). Another catheter was subsequently placed in a
femoral vein to allow infusion of solutions. A 4-lumen catheter
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(5F flow-directed thermodilution catheter, Instrumentation
Laboratory, Lexington, Massachusetts, USA) connected to a
recorder (Simultrace Recorder VR-6, Electronics for Medicine,
Honeywell, Pleasantville, New York, USA) was then inserted
into the right atrium via a jugular vein. After confirming that the
catheter was in the right atrium, as determined by pressure
readings and catheter markings, the catheter was then advanced
to the pulmonary artery and the balloon deflated. Cardiac
output was ascertained by direct read-out on an IL 601 cardiac
output computer (Instrumentation Laboratory) after injection
of 5 ml of 0°C, 0.9% saline in 2 seconds, and a representative
determination was taken as the mean of three separate readings.
Through a left flank incision, the left renal pedicle was
cautiously dissected and the renal artery isolated. Exposure of
the left renal artery was carefully performed. The renal nerves
were gently teased from the artery and the peritoneal cavity left
intact. An electromagnetic flow probe (model 400 series, Caro-
lina Medical Electronics, King, North Carolina, USA) was
placed around the exposed renal artery and renal blood flow
was measured with an electromagnetic flowmeter (model 501,
Carolina Medical Electronics). Following the placement of the
flow probe, umbilical tape was loosely tied around the renal
pedicle. Zero flow was determined by brief occlusion of the
renal artery distal to the flow probe. A 25-gauge curved needle
was gently placed into the left renal artery distal to the flow
probe and patency maintained by infusion of normal saline at
0.3 mI/mm. The right renal artery was similarly isolated and an
umbilical tape was placed around its origin from the aorta. The
left ureter was isolated and catheterized with a polyethylene
tube. The left renal vein was catheterized via the left ovarian
vein for blood sampling.
After initial blood and urine samples were drawn, a priming
dose of inulin was given, followed by a constant infusion of
0.9% NaCl at a rate of 0.8 mI/mm via a Harvard infusion pump,
containing sufficient inulin to maintain adequate blood levels.
Ten percent mannitol was infused intravenously at a rate of 0.8
mi/mm so that adequate urine samples could be obtained for
clearance measurements.
Following a 60-minute equilibration period, control data were
obtained, including systemic and renal hemodynamic parame-
ters, inulin clearance, sodium excretion, urine output and
arterial and renal venous plasma concentrations of renin activ-
ity and plasma NE. Thereafter, ANP (AA 8-33, molecular wt
2862.05) was infused into the left renal artery for 30 minutes at
1.2 sgImin (a dose previously determined not to alter systemic
hemodynamics in pilot studies) and the same experimental data
were obtained.
The aortic catheter was repositioned at the level of the left
renal artery at the end of clearance and hemodynamic measure-
ments for determination of PPF by the albumin accumulation
method. 1251-labeled albumin (Mallinckrodt Nuclear, Maryland
Heights, Missouri, USA) and cardiogreen dye were infused
simultaneously via the pulmonary artery catheter with a 2-sy-
ringe reciprocal action Harvard pump. Upon arrival of the
radioactive albumin at the renal artery (precisely determined by
detection of the cardiogreen by a densitometer), blood was
obtained via a Harvard pump from the aortic catheter at an
identical rate as the radioactive infusion. Following 10 to 15
seconds of simultaneous perfusion and collection, the umbilical
tapes around both renal arteries were tightened, thus preventing
further renal blood flow, while blood collection from the aortic
catheter was simultaneously terminated. The kidneys were then
quickly removed, frozen at —70°C for 20 minutes prior to
dissection of the papilla. The papilla was cut, weighed and
counted together with a 1 ml aliquot of the collected plasma.
PPF was determined according to the formula:
cpm/papilla (100 g)
PPF (ml/min/100 g) =
cpm/ml plasma
x
60 (sec)
perfusion time (sec)
Assay procedures
The blood samples for PRA were collected in cold tubes
containing EDTA. The blood samples for measurement of NE
were collected in chilled tubes containing 20 p1 of an additive
solution for each ml of whole blood collected. This solution
contained 95 mg/mI of ethyleneglycol-bis (13-aminoethyl
ether)-N, N'-tetraacetic acid and 60 mg/mI of reduced glutathi-
one (pH 6.0 to 7.4). Blood samples for ANP were collected in
cold tubes containing EDTA and 20 KIU/ml of aprotinin. All
specimens were immediately centrifuged in the cold to separate
plasma from cells, and stored at —70°C until analyzed.
Plasma NE was assayed with a modified radioenzymatic
technique using the Cat-a-kit (Upjohn Laboratories, Kalama-
zoo, Michigan, USA). PRA was determined by radioimmuno-
assay using the angiotensin I radioimmunoassay kit (Biotecx
Laboratories, Inc., Friendswood, Texas, USA). For measure-
ment of ANP, plasma (2 ml) was extracted by passing through
Sep-Pak C18 octadecyl silica cartridges (Waters, Milford, Mas-
sachusetts, USA), eluted with 0.1% trifluoroacetic acid in 60%
acetonitril, dried under a constant stream of air, reconstituted
with 0.5 ml radioimmunoassay buffer, and assayed by radioim-
munoassay with the use of a kit provided by Peninsula Labo-
ratories (Belmont, California, USA). The methods of assay as
well as extraction have been previously described in detail from
our laboratory [28].
Inulin was determined on an autoanalyzer (Technicon Instru-
ments, Tarrytown, New York, USA). Sodium and potassium
were determined by direct potentiometry on a NOVA 1 sodium!
potassium analyzer (NOVA Biomedical, Newton, Massachu-
setts, USA). Total plasma protein was analyzed by the Biuret
method.
Renal output of renin and NE were estimated by the differ-
ence in the renal venous and arterial concentrations multiplied
by renal plasma flow. Clearances were calculated by standard
methods.
All results are expressed as means SE. Experimental results
were subjected to one-way analysis of variance for repeated
measures, and the statistical significance was determined by
Dunnett's test. The statistical significance of the difference
between the paired or unpaired values was determined by
Student's t-test. Correlation was determined by the least square
method. P < 0.05 was considered statistically significant.
Results
Table 1 summarizes the systemic and renal hemodynamic
measurements as well as the urine flow ('çT), osmolality (Uosm)
Reiser et a!: ANP in aortocavalfistula dogs 869
Table 1. Systemic and renal hemodynamjcs, urine flow rate, osmolality, and electrolyte excretion during the control period and after ANP
infusion into the left renal artery in normal dogs
C 10mm 20mm 30mm
MAPmmHg 138±3 138±2 135±3 135
CO liter/mm 2.5 0.2 2.6 0.2
TPR mm Hg/liter/mm 57.4 4.0 53.0 2.7
Ci,, mi/mm
RBF mi/minlg
44.1 4.5
3.99 0.35
54.8 3.1k'
4.76 050b
62.5 57
4.68 O.SS
67.1
4.81
6.4a
0.58'
RVR mm Hglmllminlg
V mi/mm
37.5 4.8
0.41 0.18
32.7 5•4 b
1.80 035b
32.9 5• b
3.07 0.61a
32.2
3.95
5.6 b
0.80a
Uom mOsm/kg H20 1,348 224 665 l07 472 53 436 45
UNaV p.Eq/min 56 12 257 49 412 72 538 99
FENa %
UKV aEq/mmn
0.77 0.21
27 4
3.11 0.6la
43 4b
4.91 0.70a
57 71
6.57
59
0.93a
Values are means SE; N = 8. C, the control period; 10 mm, 20 mm, 30 mm, 10, 20, 30 minutes, respectively, after intrarenal infusion of ANP
into the left renal artery. Abbreviations are: MAP, mean arterial pressure; CO, cardiac output, TPR, total peripheral resistance; C, inulin
clearance; RBF, renal blood flow; RVR, renal vascular resistance; V, urine flow rate; U0,,, urine osmolality; UNaV, absolute sodium excretion;
FENa, fractional sodium excretion; UKV, absolute potassium excretion.
a P < 0.02; b p < 0.05 compared with C
Table 2. Systemic and renal hemodynamics, urine flow rate, osmolality, and electrolyte excretion during the control per
infusion into the left renal artery in aortocaval fistula dogs
iod and after ANP
C 10 mm 20 mm 30 mm
MAPmmHg 123±8 121±8 121±8 119±7
CO liter/mm 4.30 0.27 4.68 0.51
TPR mm Hg/liter/mm 29.5 2.7 28.7 3.6
C1 mI/mm 44 4 42 4 44 5 44 4
RBF ml/mmn/g 2.94 0.42 3.10 0.48 3.12 0.49 3.10 0.47
RVR mm HgImI/min/g
V mI/mm
46.0 7.0 46.1 8.8 43.4 6.6
0.16 0.02 0.19 0.02 0.22 0.03
42.6 5.5
0.23 0.02
Uosm mOsm/kg j2o
UNaV j.rEq/min
FENa %
UKV iiEq/min
1,311 99 1,228 113 1,181 79
1.8 0.3 3.6 0.9 4.6 1.4
0.03 0.01 0.07 0.02 0.08 0.03
15.1 2.2 21.3 3.1 28.2 4.4
1,159 83
7.5 3.3
0.12 0.05
29.5 4.8
Values are means SE; N = 9. For abbreviations, see Table 1.
and electrolyte excretion in the left kidney before and after
intrarenal ANP administration in normal dogs. Intrarenal ANP
infusion did not alter MAP, cardiac output, or total peripheral
resistance (TPR), but led to a significant ipsilateral increase in
renal blood flow (RBF) and a significant decrease in renal
vascular resistance (RVR). These changes were noted within
the first ten minutes of ANP infusion and remained essentially
unchanged during the remainder of the experiment. During the
ANP infusion, a significant and progressive increase in GFR, V,
absolute sodium and potassium excretion and fractional sodium
excretion (FENa) and a significant and progressive decrease in
Uosm was observed. The plasma sodium concentration was 145
1 mEq/liter both before and after the ANP infusion, while the
plasma potassium concentration decreased insignificantly from
a control of 3.5 0.1 to 3.3 0.1 mEq/liter following the ANP
infusion. Throughout the experiment, hematocrit remained
unchanged and was 39.3 0.6% during the control period and
39.5 0.6% following the ANP infusion.
Compared with the normal dogs, ACF dogs were all avidly
sodium retaining and demonstrated a higher cardiac output and
a lower MAP and TPR in the baseline state, prior to ANP
administration. In ACF dogs, right atrial pressure and plasma
ANP levels were 10.5 1.3 mm Hg and 163.7 pg/mi, signifi-
cantly higher than in normal dogs (0.7 0.3 mm Hg and 28.2
7.4 pg/mi, respectively). In addition, a significant positive
correlation was observed between the plasma ANP level and
right atrial pressure in normal and ACF dogs (r = 0.703; P <
0.01).
Table 2 summarizes the systemic and renal hemodynamics,
V, U0. and electrolyte excretion in the left kidney of ACF
dogs during the control period and after ANP infusion. As in the
normal dogs, intrarenal administration of ANP did not alter
cardiac output, MAP, or TPR in the ACF dogs. Unlike normal
dogs, however, there were no significant changes noted in GFR,
RBF, RVR, V. Uosm, absolute sodium or potassium excretion
or FENa. Plasma sodium and potassium concentrations in the
ACF dogs during the control period were 149 2 and 4.4 0.1
mEq/liter, respectively, and remained unchanged after the ANP
infusion. The hematocrit during the control period was 38.9
1.2% and not significantly different from 37.9 1.1% following
the ANP infusion.
Figure 1 summarizes the renin levels in arterial and renal
venous plasma in normal and ACF dogs. During the control
period, the renal venous and arterial renin levels were signifi-
cantly greater in the ACF dogs (32.7 2.1 and 22.0 2.5
nglml/hr, respectively) than in the normal dogs (3.9 1.6 and
2.7 1.1 ng/ml/hr, respectively). Net left renal output of renin
during the control period was significantly higher in the ACF
dogs as compared to the normal (19.7 4.2 vs. 3.0 1.4
U/min/g; P <0.01). Following the intrarenal infusion of ANP,
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Fig. 1. Renal venous and arterial plasma renin activity in 8 normal)
and 9 aortocavalfistula (Eli) dogs during control (C) and after intrarenal
infusion of atrial natriuretic peptide (ANP). V-A indicates the differ-
ence between venous and arterial plasma renin activity. *P < 0.01
compared with normal dogs.
both groups had significant decreases in renal venous and
arterial renin levels, however, the renin levels in the ACF dogs
still remained markedly elevated and significantly higher than
the normal dogs (21.5 2.2 vs. 1.9 0.6 and 15.3 2.1 vs. 1.9
0.7 ng/ml/hr, respectively). Similarly, following ANP admin-
istration, net left renal renin output was significantly reduced in
both groups (from 3.0 1.4 to 0.1 0.4 U/min!g in normal
dogs; P < 0.05; and from 19.7 4.2 to 11.9 2.1 U/min/g in
ACF dogs; P < 0.05), but, as noted, remained significantly
higher in the ACF dogs as compared to normal dogs (P <
0.001).
Figure 2 summarizes the NE levels in arterial and renal
venous plasma in both groups. The renal venous and arterial
plasma NE levels during the control period were significantly
higher in the ACF dogs (531 50 and 296 41 pg/mi,
respectively) than in normal dogs (149 31 and 57 6 pg/ml,
respectively). Net left renal output of NE during the control
0
Fig. 3. Papillary
(ACF dogs.
period was also significantly higher in ACF dogs as compared to
normal dogs (407 59 vs. 229 48 pg/min/g; P < 0.05).
Following the intrarenal infusion of ANP, renal venous and
arterial plasma levels of NE were not significantly different
from control in either group, however, the NE levels in ACF
dogs still remained significantly greater than in normal dogs (550
58 vs. 191 35, and 274 35 vs. 84 13 pg/mi, respective-
ly). Net left renal NE production following ANP administration
increased in both groups, but remained significantly greater in
the ACF dogs as compared to normal dogs (569 86 vs. 327
64 pg/min/g; P <0.05).
PPF in the left kidney of both groups of dogs after thirty
minutes of intrarenal ANP infusion are summarized in Figure 3.
The PPF in ACF dogs was 13.2 1.0, significantly lower than
the 28.2 3.9 mI/mm/bOg observed in the normal dogs.
Discussion
In the present study intrarenal infusion of ANP in normal
dogs, at a dose not affecting systemic hemodynamics, produced
a profound natriuresis and diuresis, associated with an increase
in GFR and RBF and a decrease in RVR. In contrast, ANP
infusion failed to bring about any of these changes in ACF dogs,
which were avidly retaining sodium despite a marked elevation
in the plasma ANP concentration with atrial distention. Al-
though ANP infusion suppressed renin release in both groups of
dogs, PRA and renal renin output remained markedly elevated
in the ACF dogs compared with the normal dogs. In addition,
the ACF dogs exhibited a significantly higher circulating plasma
NE level and renal output of this neurotransmitter than the
normal dogs both before and after ANP infusion. Associated
Arterial
I
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plasma flow in 8 normal and 9 aortocaval fistula
Fig. 2. Renal venous and arterial plasma norepinephrine in 8 normal
(•) and 9 aortocaval fistula (LII) dogs during control (C) and after
intrarenal infusion of atrial natriuretic peptide (ANP). V-A indicates
the difference between venous and arterial plasma norepinephrine
concentration. *p < 0.01 and tP < 0.05 compared with normal dogs.
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with activation of these vasoactive systems, a markedly re-
duced PPF was observed in the ACF dogs after ANP infusion.
The renal hemodynamic changes noted in normal dogs were
apparent within the first 10 minutes and remained unchanged
during the remaining experimental period of ANP infusion.
However, increases in GFR, natriuresis, diuresis and loss of
urinary concentration proceeded in a progressive manner. The
quantitative contribution of the ANP-induced renal hemody-
namic alterations to the natriuresis and diuresis has remained
controversial. Some studies showed natriuresis and diuresis
without changes in GFR and RBF [7, 27, 29—311, whereas others
emphasized the importance of the renal hemodynamic alter-
ations [2, 3, 32, 33]. These divergent results can not be easily
explained, but may be related to different concentrations of
ANP reaching the sites of action in the kidney, the volume
status of the subjects studied, and the degree of activity of
vasoactive systems which possibly modulate ANP actions. The
renal vascular responses to ANP may also be more susceptible
to intervention by neurohumoral systems than are the ANP
effects on the tubules, leading to variable results. Regardless of
the variations in renal hemodynamic responses to ANP, the
natriuresis is likely to be augmented when GFR is increased
after exogenous administration of ANP [31].
Several studies have provided compelling evidence that the
inner medullary collecting duct is the predominant tubular site
where ANP inhibits sodium reabsorption [7, 8, 291. In addition,
ANP diminishes water permeability in the collecting duct [34].
A mathematical simulation model has recently quantified that
50% inhibition of sodium and water transport in the collecting
duct is sufficient to account for most of the natriuresis and
diuresis caused by ANP [35]. Since sodium and water reab-
sorbed in the inner medulla return only to ascending vasa recta
[361, alterations in inner medullary hemodynamics would be
required to maximize the action of ANP. Of relevance is the
recent observation of a high hydraulic conductivity and sodium
permeability in the ascending vasa recta, properties rendering
water and sodium uptake into these capillaries highly sensitive
to pressure changes [37, 38]. Although several studies have
produce inconsistent results regarding the effect of ANP on PPF
or papillary blood flow [1, 4—6], they do not provide direct
information on changes in oncotic and hydraulic pressure
induced by ANP. In the study where direct measurements of
pressure were made, ANP was found to raise hydraulic pres-
sure in the papillary capillaries, preventing fluid from returning
to these vessels [39]. Taken together, the full expression of
natriuresis, diuresis and suppression of urinary concentration
by ANP could not solely depend on inhibition of tubular
transport but would require incorporation of its vascular effects
on the glomerular and inner medullary circulation.
Our ACF dogs had a high cardiac output, markedly reduced
TPR, activation of the renin-angiotensin and adrenergic sys-
tems as has been previously described in this model of chronic
sodium retention [11, 40, 41]. It is apparent that the high right
atrial pressure consequent to formation of the fistula led to a
large increase in endogenous ANP release, as has been shown
in other models with atrial distention [26, 42—45]. Despite a
marked elevation of plasma ANP level at baseline, sodium
retention was evident and infusion of ANP at a concentration
approximately 40-fold greater than the circulating level, ACF
dogs demonstrated neither the renal hemodynamic nor urinary
excretory effects observed in normal dogs.
Prior studies in experimental models of heart failure or in
patients with cardiac failure have shown discrepant renal re-
sponses to exogenous ANP infusion. Some have noted a
natriuresis and diuresis [17—19, 23, 25, 46] while others have
observed either a blunted [13, 15, 16, 21, 25, 47] or absent renal
response [14, 22, 26] following ANP infusion. These varied
results may be explained by diverse degrees of sodium avidity
and activation of neurohumoral systems at the time of study.
Previous studies by us [48] and others [24, 25] have demon-
strated that chronic caval dogs (a model of low cardiac output)
and ACF animals begin with a phase of profound sodium
retention, associated with a marked activation of the neuro-
humoral systems which promote sodium retention and genera-
tion of ascites and edema. This phase may be followed by a
second stage in which there is maintenance of extracellular
volume expansion, but a return to sodium balance associated
with deactivation of the renin-angiotensin-aldosterone system
[24, 25, 48]. This dynamic transition from sodium retention to
normal sodium balance has also been observed in salt-retaining
patients with heart failure [49—51]. A detailed examination of
published reports reveals that avid sodium retention markedly
attenuates the natriuretic response to ANP, which will be
unmasked when sodium retention becomes less apparent. In
both experimental models of heart failure and in the studies of
patients with cardiac failure cited above, a natriuretic response
to ANP was observed only when a high baseline urinary sodium
excretion and modest activation of the renin-angiotensin system
existed. A careful analysis of the previously reported experi-
mental data reveals a strong correlation between the maximal
urinary sodium excretion after ANP administration and the
basal sodium excretion rate as illustrated in Figure 4. It would
appear then, that the degree of sodium avidity predicts the
response to ANP in heart failure.
The findings of Levy [52] and Maher, Cernacek and Levy [24,
46] take exception to this relationship between sodium avidity
and ANP-induced natriuresis in chronic caval dogs. These
investigators observed two divergent responses to ANP in
sodium retaining caval dogs. Although not differentiated by
systemic or renal hemodynamics or plasma levels of renin and
aldosterone, half of the animals had a diuretic and natriuretic
response to ANP, whereas the remaining half showed no
response. No distinction between the two groups could be made
in plasma ANP levels or in renal hemodynamics after ANP
infusion. Both groups also demonstrated similar urinary excre-
tion of cGMP, a marker of ANP effect, and exhibited similarly
reduced PPF. Neither renal vasodilation nor renal denervation
could convert ANP nonresponders to responders. They showed
that the absence of a natriuretic response to ANP was unique
because these animals responded to multiple diuretics as did the
responding animals. The data in the present study do not
exclude the possibility of a defective tubular response to ANP
as a basis for the lack of natriuresis with ANP infusion in ACF
dogs as suggested by Levy and co-workers; however, caval and
ACF dogs differ widely with respect to plasma ANP levels in
that ANP release is substantially reduced in caval dogs [24, 52]
so that the explanation offered for these animals may not be
applicable to ACF dogs.
The intrarenal infusion of ANP in our normal dogs led to a
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Fig. 4. Correlation between absolute urinary
sodium excretion (UNV) before and after
administration of atrial natriuretic peptide
(ANP). The data points are obtained by
review of previous studies in patients or
120 experimental models of heart failure. The
numbers inside parentheses denote reference
numbers. r 0.917, P < 0.001.
significant reduction in renin secretion. In ACF dogs, ANP
infusion also decreased renin secretion despite profound acti-
vation of the renin-angiotensin system; however, PRA and
renin secretory rate still remained markedly elevated as com-
pared with normal dogs. It is conceivable that the large amounts
of angioten sin II generated in the kidney not only act on tubular
sites proximal to the collecting duct to enhance sodium reten-
tion, but also interfere with the vasorelaxant effects of ANP.
Unlike the effect of ANP on renin release, this peptide did not
significantly change the circulating level and renal output of NE
in either normal or ACF dogs. This response to ANP was
similarly noted by Koepke and DiBona [16] in their study of
normal and heart failure dogs given a continuous incremental
intravenous infusion of ANP. Release of NE from the kidney
has been shown to directly correlate with the degree of renal
nerve stimulation [53] and, as anticipated, renal NE production
remained significantly greater in the ACF dogs than in the
normal dogs. The proximal tubules and thick ascending limb of
Henle's loop, as well as intrarenal resistance vessels, are richly
endowed with adrenergic nerves [54]. Together with the aug-
mented renin release, the highly stimulated aclrenergic activity
may act at multiple tubular and vascular sites, preventing ANP
from manifesting its effects.
Elevated levels of plasma ANP, as seen in the heart failure
models and the present study, if associated with down-regula-
tion of ANP receptor sites within the kidney, could account for
the apparent lack of response to exogenously administered
ANP. Studies in rats have shown an inverse relationship
between plasma ANP concentrations and ANP receptor sites in
the glomerulus and papilla [55—57]. However, a study by Martin
et al [58] has demonstrated the existence of two distinct ANP
receptor subtypes, one of which was functional and shown to be
coupled to guanylate cyclase activity while the other was not.
The coupled receptor subtype was expressed both in glomeruli
and papillary epithelial cells, and was unchanged in number in
response to acute changes in volume status. Similar densities of
the guanylate cyclase coupled ANP receptor were also found in
spontaneous hypertensive rats with chronically elevated plasma
ANP levels, and in Wistar Kyoto rats which had significantly
lower levels of circulating ANP [58]. These findings argue that
down-regulation of ANP receptor sites within the kidney could
not account for the differences found in the heart failure studies.
In fact, endogenous ANP plasma levels, when measured in the
studies cited previously, were all found to be elevated, and did
not correlate with the level of response to exogenous ANP
administration.
PPF has been shown to be inversely proportional to the
activation of the renin-angiotensin system [36], and was mark-
edly reduced in ACF dogs after ANP administration in the
present study. The PPF observed was similar to that described
earlier by us in the ACF dogs not receiving ANP [11], suggest-
ing that ANP did not significantly alter PPF. Since hydraulic
and oncotic pressure in the papillary capillaries have not yet
been measured in any sodium-retaining model, it is not possible
to assess the contribution of the low PPF to the failure of ANP
to elicit a natriuresis. Nevertheless, in the face of reduced PPF
it is probable that hydraulic pressure in the papillary vasa recta
was low, favoring sodium and water retention.
In conclusion, our findings suggest that the renal response to
ANP in the ACF dog model and other models of heart failure is
largely influenced by the extent of sodium avidity which is
linked to the degree of stimulation of neurohumoral systems
controlling sodium balance. Specifically, the augmented release
of neurohumoral mediators of sodium retention, including an-
giotensin II and NE, may abrogate the natriuretic and diuretic
actions of endogenous or exogenously administered ANP by
their direct effects on tubular transport and/or by their intra-
renal hemodynamic actions.
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